1. Home
  2. Labeler Index
  3. Zydus Lifesciences Limited
  4. 70771-1753
  5. Product Images: Mirabegron

Product Images Mirabegron

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. structure - 9dd396b5 4841 483a b63b 63a0e3cea1ae 01
  2. Figure 1 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 02
  3. Figure 2 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 03
  4. Figure 3 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 04
  5. Figure 4 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 05
  6. Figure 5 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 06
  7. Figure 6 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 07
  8. Figure 7 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 08
  9. Figure 8 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 09
  10. Mirabegron extended-release tablets, 25mg - 9dd396b5 4841 483a b63b 63a0e3cea1ae 10
  11. Mirabegron extended-release tablets, 50mg - 9dd396b5 4841 483a b63b 63a0e3cea1ae 11

Product Label Images

The following 11 images provide visual information about the product associated with Mirabegron NDC 70771-1753 by Zydus Lifesciences Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

structure - 9dd396b5 4841 483a b63b 63a0e3cea1ae 01

structure - 9dd396b5 4841 483a b63b 63a0e3cea1ae 01

Figure 1 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 02

Figure 1 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 02

Figure 2 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 03

Figure 2 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 03

Figure 3 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 04

Figure 3 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 04

Figure 4 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 05

Figure 4 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 05

Figure 5 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 06

Figure 5 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 06

Figure 6 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 07

Figure 6 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 07

Figure 7 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 08

Figure 7 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 08

This text contains data related to mean changes from baseline measurements. The measurements range from 0.00 to -2.00, with various increments in between. There are also references to weeks and different treatments, including a placebo and a drug called mirobegron. It seems to be a comparison between the effects of different doses or treatments on a specific parameter.*

Figure 8 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 09

Figure 8 - 9dd396b5 4841 483a b63b 63a0e3cea1ae 09

Mirabegron extended-release tablets, 25mg - 9dd396b5 4841 483a b63b 63a0e3cea1ae 10

Mirabegron extended-release tablets, 25mg - 9dd396b5 4841 483a b63b 63a0e3cea1ae 10

Mirabegron extended-release tablets, 50mg - 9dd396b5 4841 483a b63b 63a0e3cea1ae 11

Mirabegron extended-release tablets, 50mg - 9dd396b5 4841 483a b63b 63a0e3cea1ae 11

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.